1. Epstein-Barr virus-induced ectopic CD137 expression helps nasopharyngeal carcinoma to escape immune surveillance and enables targeting by chimeric antigen receptors

   • Mukul Prasad
   • Sashigala Ponnalagu
   • Herbert Schwarz

   Original Article 17 March 2022 Pages: 2583 - 2596

   

2. Camrelizumab combined with apatinib and S-1 as second-line treatment for patients with advanced gastric or gastroesophageal junction adenocarcinoma: a phase 2, single-arm, prospective study

   • Chao Jing
   • Junyun Wang
   • Wei Deng

   Original Article 18 March 2022 Pages: 2597 - 2608

   

3. Evolution of bone metastases in patients receiving at least three months of checkpoint inhibitors

   • E. Gefard-Gontier
   • R. Markich
   • M. Kostine

   Original Article 19 March 2022 Pages: 2609 - 2618

   

4. Altered immunity to microbiota, B cell activation and depleted γδ/resident memory T cells in colorectal cancer

   • Alistair Noble
   • Edward T. Pring
   • Stella C. Knight

   Original Article Open access 22 March 2022 Pages: 2619 - 2629

   

5. Lenvatinib plus pembrolizumab for systemic therapy-naïve and -experienced unresectable hepatocellular carcinoma

   • Chi-Jung Wu
   • Pei-Chang Lee
   • Yi-Hsiang Huang

   Original Article Open access 28 March 2022 Pages: 2631 - 2643

   

6. The expression of PD-1 ligand 1 on macrophages and its clinical impacts and mechanisms in lung adenocarcinoma

   • Yusuke Shinchi
   • Shiho Ishizuka
   • Makoto Suzuki

   Original Article 29 March 2022 Pages: 2645 - 2661

   

7. CXCL9-modified CAR T cells improve immune cell infiltration and antitumor efficacy

   • Yonggui Tian
   • Chunli Wen
   • Yi Zhang

   Original Article 29 March 2022 Pages: 2663 - 2675

   

8. OIT3 mediates macrophage polarization and facilitates hepatocellular carcinoma progression

   • Shuai Yang
   • Jiangang Zhang
   • Yongsheng Li

   Original Article 30 March 2022 Pages: 2677 - 2689

   

9. Functional antigen processing and presentation mechanism as a prerequisite factor of response to treatment with dendritic cell vaccines and anti-PD-1 in preclinical murine LLC1 and GL261 tumor models

   • Karolina Žilionytė
   • Ugnė Bagdzevičiūtė
   • Vita Pašukonienė

   Original Article 01 April 2022 Pages: 2691 - 2700

   

10. Correction to: Functional antigen processing and presentation mechanism as a prerequisite factor of response to treatment with dendritic cell vaccines and anti-PD-1 in preclinical murine LLC1 and GL261 tumor models

    • Karolina Žilionytė
    • Ugnė Bagdzevičiūtė
    • Vita Pašukonienė

    Correction 25 April 2022 Pages: 2701 - 2701

11. Evaluation of the efficacy and safety of TAS0313 in adults with recurrent glioblastoma

    • Yoshitaka Narita
    • Yoshiko Okita
    • Yoshiki Arakawa

    Original Article Open access 04 April 2022 Pages: 2703 - 2715

    

12. Tumor-derived exosomes drive pre-metastatic niche formation in lung via modulating CCL1⁺ fibroblast and CCR8⁺ Treg cell interactions

    • Ming Wang
    • Zhongyu Qin
    • Zhihai Qin

    Original Article 15 April 2022 Pages: 2717 - 2730

    

13. The soluble form of CD160 acts as a tumor mediator of immune escape in melanoma

    • Marie-Léa Gauci
    • Jérôme Giustiniani
    • Anne Marie-Cardine

    Original Article Open access 15 April 2022 Pages: 2731 - 2742

    

14. Prognostic significance of NY-ESO-1 antigen and PIGR expression in esophageal tumors of CHP-NY-ESO-1-vaccinated patients as adjuvant therapy

    • Yasuhiro Nagata
    • Shinichi Kageyama
    • Hiroshi Shiku

    Original Article 16 April 2022 Pages: 2743 - 2755

    

15. Serial interferon-gamma release assay in lung cancer patients receiving immune checkpoint inhibitors: a prospective cohort study

    • Kohei Fujita
    • Paul Elkington
    • Tadashi Mio

    Original Article 16 April 2022 Pages: 2757 - 2764

    

16. Role of the cGAS-STING pathway in regulating the tumor-immune microenvironment in dMMR/MSI colorectal cancer

    • Akinao Kaneta
    • Shotaro Nakajima
    • Koji Kono

    Original Article 16 April 2022 Pages: 2765 - 2776

    

17. Establishment of a mechanism-based in vitro coculture assay for evaluating the efficacy of immune checkpoint inhibitors

    • Myeong Joon Kim
    • Kyeong Hee Hong
    • Sang-Jun Ha

    Original Article 18 April 2022 Pages: 2777 - 2789

    

18. Gene expression profile of high PD-L1 non-small cell lung cancers refractory to pembrolizumab

    • Jamila Talb
    • Paul Takam Kamga
    • Etienne Giroux Leprieur

    Original Article 18 April 2022 Pages: 2791 - 2799

    

19. Chimeric antigen receptor clustering via cysteines enhances T-cell efficacy against tumor

    • Yuedi Wang
    • Yiyuan Gao
    • Yiwei Chu

    Original Article 19 April 2022 Pages: 2801 - 2814

    

20. Clinical and molecular correlates of response to immune checkpoint blockade in urothelial carcinoma with liver metastasis

    • Takashi Yoshida
    • Chisato Ohe
    • On behalf of the Japan Urological Oncology Group

    Original Article 20 April 2022 Pages: 2815 - 2828

    

21. Tafasitamab mediates killing of B-cell non-Hodgkin’s lymphoma in combination with γδ T cell or allogeneic NK cell therapy

    • Jung Hyun Her
    • Dominik Pretscher
    • Jan Endell

    Research Report Open access 29 March 2022 Pages: 2829 - 2836